intellia - Search News

Intellia Pauses Gene Therapy Trials

Intellia pauses phase 3 CRISPR trials after patient is hospitalized

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in the ATTR-CM trial. The patient was hospitalized, is being closely monitored and is undergoing treatment, according to the biotech.

BioSpace · 2d

Intellia Pauses Phase III ATTR Trials for CRISPR Gene Therapy After Life-Threatening Liver Toxicity

· 2d · on MSN

Intellia pauses gene therapy trials after patient suffers liver injury, shares slide

23hon MSN

Intellia hit with multiple downgrades following pause in phase 3 nex-z program

At least five Wall Street firms have downgraded their ratings on Intellia Therapeutics (NASDAQ:NTLA) in the wake of the ...

2don MSN

Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial

Intellia shares were down 40% in late morning trading. On an investor call, Intellia’s CEO, John Leonard, said that the ...

BioPharma Dive

Intellia pauses two CRISPR drug studies after safety scare

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

23h

CRISPR Crisis: Intellia Stock Crashes 40% After Shock Trial Pause

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

Some results have been hidden because they may be inaccessible to you